Drug Profile
Egalet 003
Alternative Names: AD opioid; Egalet-003; Opioid 3Latest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Egalet
- Developer Assertio Therapeutics
- Class Morphinans; Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 20 May 2020 Assertio Therapeutics has been merged with Zyla Life Sciences to form Assertio Therapeutics
- 03 Jun 2019 Egalet 003 is available for licensing as of 31 Dec 2018
- 31 Dec 2018 Discontinued - Preclinical for Pain in Denmark (PO), as the company is exploring possibilities for further development